|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MPV17L |
Gene summary for MPV17L |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MPV17L | Gene ID | 255027 |
| Gene name | MPV17 mitochondrial inner membrane protein like | |
| Gene Alias | M-LPH | |
| Cytomap | 16p13.11 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q2QL34 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 255027 | MPV17L | P2T-E | Human | Esophagus | ESCC | 6.90e-05 | 4.07e-02 | 0.1177 |
| 255027 | MPV17L | P12T-E | Human | Esophagus | ESCC | 1.31e-05 | 4.17e-02 | 0.1122 |
| 255027 | MPV17L | P24T-E | Human | Esophagus | ESCC | 3.57e-18 | 3.93e-01 | 0.1287 |
| 255027 | MPV17L | P32T-E | Human | Esophagus | ESCC | 3.23e-25 | 5.31e-01 | 0.1666 |
| 255027 | MPV17L | P49T-E | Human | Esophagus | ESCC | 9.78e-03 | 4.95e-01 | 0.1768 |
| 255027 | MPV17L | P56T-E | Human | Esophagus | ESCC | 1.63e-03 | 4.69e-01 | 0.1613 |
| 255027 | MPV17L | P62T-E | Human | Esophagus | ESCC | 2.08e-03 | 8.64e-02 | 0.1302 |
| 255027 | MPV17L | P91T-E | Human | Esophagus | ESCC | 3.38e-11 | 8.13e-01 | 0.1828 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0022613111 | Esophagus | ESCC | ribonucleoprotein complex biogenesis | 365/8552 | 463/18723 | 1.74e-49 | 1.11e-45 | 365 |
| GO:0042254111 | Esophagus | ESCC | ribosome biogenesis | 252/8552 | 299/18723 | 3.27e-44 | 1.04e-40 | 252 |
| GO:2001233111 | Esophagus | ESCC | regulation of apoptotic signaling pathway | 256/8552 | 356/18723 | 4.11e-24 | 1.04e-21 | 256 |
| GO:0006839110 | Esophagus | ESCC | mitochondrial transport | 187/8552 | 254/18723 | 8.35e-20 | 9.81e-18 | 187 |
| GO:014005313 | Esophagus | ESCC | mitochondrial gene expression | 93/8552 | 108/18723 | 1.96e-18 | 2.03e-16 | 93 |
| GO:0006417111 | Esophagus | ESCC | regulation of translation | 304/8552 | 468/18723 | 1.53e-17 | 1.33e-15 | 304 |
| GO:003254314 | Esophagus | ESCC | mitochondrial translation | 68/8552 | 76/18723 | 1.02e-15 | 6.86e-14 | 68 |
| GO:2001234111 | Esophagus | ESCC | negative regulation of apoptotic signaling pathway | 161/8552 | 224/18723 | 1.24e-15 | 8.09e-14 | 161 |
| GO:0045727111 | Esophagus | ESCC | positive regulation of translation | 107/8552 | 136/18723 | 2.79e-15 | 1.68e-13 | 107 |
| GO:0034250111 | Esophagus | ESCC | positive regulation of cellular amide metabolic process | 123/8552 | 162/18723 | 3.32e-15 | 1.93e-13 | 123 |
| GO:000700619 | Esophagus | ESCC | mitochondrial membrane organization | 93/8552 | 116/18723 | 2.16e-14 | 1.11e-12 | 93 |
| GO:0010821110 | Esophagus | ESCC | regulation of mitochondrion organization | 107/8552 | 144/18723 | 2.31e-12 | 9.41e-11 | 107 |
| GO:0008637110 | Esophagus | ESCC | apoptotic mitochondrial changes | 83/8552 | 107/18723 | 1.43e-11 | 5.08e-10 | 83 |
| GO:0010639110 | Esophagus | ESCC | negative regulation of organelle organization | 215/8552 | 348/18723 | 8.20e-10 | 2.01e-08 | 215 |
| GO:0042255111 | Esophagus | ESCC | ribosome assembly | 50/8552 | 61/18723 | 5.66e-09 | 1.17e-07 | 50 |
| GO:004690217 | Esophagus | ESCC | regulation of mitochondrial membrane permeability | 49/8552 | 63/18723 | 1.91e-07 | 2.97e-06 | 49 |
| GO:00905599 | Esophagus | ESCC | regulation of membrane permeability | 58/8552 | 78/18723 | 2.38e-07 | 3.61e-06 | 58 |
| GO:00357948 | Esophagus | ESCC | positive regulation of mitochondrial membrane permeability | 36/8552 | 43/18723 | 2.90e-07 | 4.20e-06 | 36 |
| GO:009734510 | Esophagus | ESCC | mitochondrial outer membrane permeabilization | 28/8552 | 32/18723 | 1.02e-06 | 1.29e-05 | 28 |
| GO:190268614 | Esophagus | ESCC | mitochondrial outer membrane permeabilization involved in programmed cell death | 33/8552 | 40/18723 | 1.80e-06 | 2.11e-05 | 33 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MPV17L | SNV | Missense_Mutation | c.485C>T | p.Thr162Ile | p.T162I | Q2QL34 | protein_coding | tolerated(0.41) | benign(0.006) | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| MPV17L | SNV | Missense_Mutation | c.514N>C | p.Asp172His | p.D172H | Q2QL34 | protein_coding | deleterious(0) | probably_damaging(0.972) | TCGA-C8-A12Z-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
| MPV17L | SNV | Missense_Mutation | c.212N>T | p.Glu71Val | p.E71V | Q2QL34 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MPV17L | SNV | Missense_Mutation | c.457G>A | p.Ala153Thr | p.A153T | Q2QL34 | protein_coding | tolerated(1) | benign(0) | TCGA-CM-6171-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MPV17L | SNV | Missense_Mutation | c.475N>A | p.Leu159Ile | p.L159I | Q2QL34 | protein_coding | tolerated(0.23) | benign(0.081) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| MPV17L | SNV | Missense_Mutation | novel | c.334N>A | p.Asp112Asn | p.D112N | Q2QL34 | protein_coding | tolerated(0.06) | possibly_damaging(0.694) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| MPV17L | SNV | Missense_Mutation | novel | c.194N>C | p.Val65Ala | p.V65A | Q2QL34 | protein_coding | tolerated(0.58) | benign(0.001) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MPV17L | SNV | Missense_Mutation | c.371N>C | p.Asn124Thr | p.N124T | Q2QL34 | protein_coding | tolerated(0.21) | possibly_damaging(0.506) | TCGA-D1-A1NX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD | |
| MPV17L | SNV | Missense_Mutation | novel | c.329N>T | p.Gly110Val | p.G110V | Q2QL34 | protein_coding | deleterious(0.01) | possibly_damaging(0.858) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MPV17L | SNV | Missense_Mutation | novel | c.528N>T | p.Lys176Asn | p.K176N | Q2QL34 | protein_coding | tolerated(0.09) | benign(0.057) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |